What this study finds is exactly what vaccine developer Geert Vanden Bossche (Belgium) has been predicting.  The predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. [DATA LINK HERE]